Camrelizumab Explained
| Type: | mab |
| Mab Type: | mab |
| Source: | zu |
| Target: | PD1 |
| Cas Number: | 1798286-48-2 |
| Unii: | 73096E137E |
| Atc Prefix: | none |
| Synonyms: | SHR-1210 |
Camrelizumab (SHR-1210) (INN[1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2]
This drug is being developed by Jiangsu HengRui Medicine Co., Ltd., camrelizumab is undergoing Phase II/III trials.
Notes and References
- World Health Organization . International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77 . WHO Drug Information . 31 . 1 . 2017 . World Health Organization .
- Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, Li X, Liu J, Ku W, Zhang Y, Chen M, An X, Shi L, Brock MV, Bai J, Han W . 6 . Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma . Journal of Clinical Oncology . 37 . 17 . 1479–1489 . June 2019 . 31039052 . 10.1200/JCO.18.02151 . 141482897 . free .
